Fluoxetine prevents dystrophic changes in a zebrafish model of duchenne muscular dystrophy

Trent A. Waugh, Eric Horstick, Junguk Hur, Samuel W. Jackson, Ann E. Davidson, Xingli Li, James J. Dowling

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Duchenne muscular dystrophy(DMD)is a common and relentlessly progressive muscle disease.Some interventions have been identified that modestly slow progression and prolong survival, but more meaningful therapies are lacking. The goal of this study is to identify new therapeutic pathways for DMD using a zebrafish model of the disease. To accomplish this, we performed a non-biased drug screen in sapje, a zebrafish line with a recessive nonsense mutation in dystrophin. We identified 6 positive hits (out of 640 total drugs tested) by their ability to prevent abnormal birefringence in sapje. Follow-up analyses demonstrated that fluoxetine, a selective serotonin reuptake inhibitor (SSRI), provided the most substantial benefit. Morpholino-based experimentation confirmed that modulation of the serotonin pathway alone can prevent the dystrophic phenotype, and transcriptomic analysis revealed changes in calcium homeostasis as a potential mechanism. In all, we demonstrate that monoamine agonists can prevent disease in a vertebrate model of DMD. Given the safe and widespread use of SSRIs in clinical practice, our study identifies an attractive target pathway for therapy development.

Original languageEnglish (US)
Article numberddu185
Pages (from-to)4651-4662
Number of pages12
JournalHuman Molecular Genetics
Volume23
Issue number17
DOIs
StatePublished - Sep 2014

Fingerprint

Duchenne Muscular Dystrophy
Fluoxetine
Zebrafish
Birefringence
Morpholinos
Dystrophin
Nonsense Codon
Serotonin Uptake Inhibitors
Pharmaceutical Preparations
Vertebrates
Serotonin
Homeostasis
Therapeutics
Calcium
Phenotype
Muscles

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Waugh, T. A., Horstick, E., Hur, J., Jackson, S. W., Davidson, A. E., Li, X., & Dowling, J. J. (2014). Fluoxetine prevents dystrophic changes in a zebrafish model of duchenne muscular dystrophy. Human Molecular Genetics, 23(17), 4651-4662. [ddu185]. https://doi.org/10.1093/hmg/ddu185

Fluoxetine prevents dystrophic changes in a zebrafish model of duchenne muscular dystrophy. / Waugh, Trent A.; Horstick, Eric; Hur, Junguk; Jackson, Samuel W.; Davidson, Ann E.; Li, Xingli; Dowling, James J.

In: Human Molecular Genetics, Vol. 23, No. 17, ddu185, 09.2014, p. 4651-4662.

Research output: Contribution to journalArticle

Waugh, TA, Horstick, E, Hur, J, Jackson, SW, Davidson, AE, Li, X & Dowling, JJ 2014, 'Fluoxetine prevents dystrophic changes in a zebrafish model of duchenne muscular dystrophy', Human Molecular Genetics, vol. 23, no. 17, ddu185, pp. 4651-4662. https://doi.org/10.1093/hmg/ddu185
Waugh, Trent A. ; Horstick, Eric ; Hur, Junguk ; Jackson, Samuel W. ; Davidson, Ann E. ; Li, Xingli ; Dowling, James J. / Fluoxetine prevents dystrophic changes in a zebrafish model of duchenne muscular dystrophy. In: Human Molecular Genetics. 2014 ; Vol. 23, No. 17. pp. 4651-4662.
@article{c09d367051b5462c939878f02a004102,
title = "Fluoxetine prevents dystrophic changes in a zebrafish model of duchenne muscular dystrophy",
abstract = "Duchenne muscular dystrophy(DMD)is a common and relentlessly progressive muscle disease.Some interventions have been identified that modestly slow progression and prolong survival, but more meaningful therapies are lacking. The goal of this study is to identify new therapeutic pathways for DMD using a zebrafish model of the disease. To accomplish this, we performed a non-biased drug screen in sapje, a zebrafish line with a recessive nonsense mutation in dystrophin. We identified 6 positive hits (out of 640 total drugs tested) by their ability to prevent abnormal birefringence in sapje. Follow-up analyses demonstrated that fluoxetine, a selective serotonin reuptake inhibitor (SSRI), provided the most substantial benefit. Morpholino-based experimentation confirmed that modulation of the serotonin pathway alone can prevent the dystrophic phenotype, and transcriptomic analysis revealed changes in calcium homeostasis as a potential mechanism. In all, we demonstrate that monoamine agonists can prevent disease in a vertebrate model of DMD. Given the safe and widespread use of SSRIs in clinical practice, our study identifies an attractive target pathway for therapy development.",
author = "Waugh, {Trent A.} and Eric Horstick and Junguk Hur and Jackson, {Samuel W.} and Davidson, {Ann E.} and Xingli Li and Dowling, {James J.}",
year = "2014",
month = "9",
doi = "10.1093/hmg/ddu185",
language = "English (US)",
volume = "23",
pages = "4651--4662",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "17",

}

TY - JOUR

T1 - Fluoxetine prevents dystrophic changes in a zebrafish model of duchenne muscular dystrophy

AU - Waugh, Trent A.

AU - Horstick, Eric

AU - Hur, Junguk

AU - Jackson, Samuel W.

AU - Davidson, Ann E.

AU - Li, Xingli

AU - Dowling, James J.

PY - 2014/9

Y1 - 2014/9

N2 - Duchenne muscular dystrophy(DMD)is a common and relentlessly progressive muscle disease.Some interventions have been identified that modestly slow progression and prolong survival, but more meaningful therapies are lacking. The goal of this study is to identify new therapeutic pathways for DMD using a zebrafish model of the disease. To accomplish this, we performed a non-biased drug screen in sapje, a zebrafish line with a recessive nonsense mutation in dystrophin. We identified 6 positive hits (out of 640 total drugs tested) by their ability to prevent abnormal birefringence in sapje. Follow-up analyses demonstrated that fluoxetine, a selective serotonin reuptake inhibitor (SSRI), provided the most substantial benefit. Morpholino-based experimentation confirmed that modulation of the serotonin pathway alone can prevent the dystrophic phenotype, and transcriptomic analysis revealed changes in calcium homeostasis as a potential mechanism. In all, we demonstrate that monoamine agonists can prevent disease in a vertebrate model of DMD. Given the safe and widespread use of SSRIs in clinical practice, our study identifies an attractive target pathway for therapy development.

AB - Duchenne muscular dystrophy(DMD)is a common and relentlessly progressive muscle disease.Some interventions have been identified that modestly slow progression and prolong survival, but more meaningful therapies are lacking. The goal of this study is to identify new therapeutic pathways for DMD using a zebrafish model of the disease. To accomplish this, we performed a non-biased drug screen in sapje, a zebrafish line with a recessive nonsense mutation in dystrophin. We identified 6 positive hits (out of 640 total drugs tested) by their ability to prevent abnormal birefringence in sapje. Follow-up analyses demonstrated that fluoxetine, a selective serotonin reuptake inhibitor (SSRI), provided the most substantial benefit. Morpholino-based experimentation confirmed that modulation of the serotonin pathway alone can prevent the dystrophic phenotype, and transcriptomic analysis revealed changes in calcium homeostasis as a potential mechanism. In all, we demonstrate that monoamine agonists can prevent disease in a vertebrate model of DMD. Given the safe and widespread use of SSRIs in clinical practice, our study identifies an attractive target pathway for therapy development.

UR - http://www.scopus.com/inward/record.url?scp=84905647550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905647550&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddu185

DO - 10.1093/hmg/ddu185

M3 - Article

C2 - 24760771

AN - SCOPUS:84905647550

VL - 23

SP - 4651

EP - 4662

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 17

M1 - ddu185

ER -